{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:53:57Z","timestamp":1773842037214,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> No consensus has been reached regarding the optimal therapy for visceral leishmaniasis (VL), which affects ~12 million people worldwide.<\/jats:p><jats:p><jats:bold>Case Presentation:<\/jats:bold> This report described four cases of VL encountered in the First Affiliated Hospital of Xi'an Jiaotong University between October 2019 and December 2020. Of the four patients, one patient experienced relapse after antimonial treatment, and the remaining patients had primary VL (including one patient with impaired kidney function and one patient with hemophagocytic syndrome). All patients received a novel treatment protocol, namely the low-dose L-AmB therapy, which was characterized by a low initial dose, cautious dose escalation, and low-dose therapy as maintenance. All patients were cured without severe complications, and there was no further recurrence during follow-up.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This case series demonstrated the safety and efficacy of the low-dose L-AmB therapy for VL patients, providing novel treatment protocol for the VL.<\/jats:p>","DOI":"10.3389\/fmed.2021.766400","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:00:14Z","timestamp":1637132414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Use of Liposomal Amphotericin B in Low Doses in Patients With Visceral Leishmaniasis"],"prefix":"10.3389","volume":"8","author":[{"given":"Danfeng","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenya","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunying","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanhu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1128\/CMR.00080-14","article-title":"Visceral Leishmaniasis in China: an endemic disease under control","volume":"28","author":"Lun","year":"2015","journal-title":"Clin Microbiol Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3855\/jidc.6833","article-title":"Recent updates and perspectives on leishmaniasis","volume":"9","author":"Savoia","year":"2015","journal-title":"J Infect Dev Ctries."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8463097","article-title":"Incidence and trends of leishmaniasis and its risk factors in humera, Western Tigray","volume":"2018","author":"Gebremichael Tedla","year":"2018","journal-title":"J Parasitol Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2214-109X(13)70118-9","article-title":"Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study","volume":"2","author":"Mondal","year":"2014","journal-title":"Lancet Glob Health."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e3131","DOI":"10.1371\/journal.pntd.0003131","article-title":"Visceral leishmaniasis in Ethiopia: an evolving disease","volume":"8","author":"Leta","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.11847\/zggws1115469","article-title":"al E. Prevalence characteristics and space-time clustering of leishmaniasis in Shaanxi province","volume":"34","author":"Lin","year":"2018","journal-title":"Chin J Public Health."},{"key":"B8","first-page":"431","article-title":"Epidemiological characteristics of Kala-azar disease in China, during 2005-2015","volume":"38","author":"Zheng","year":"2017","journal-title":"Chin J Epidemiol."},{"key":"B9","first-page":"357","article-title":"Investigation on the Outbreak of Visceral Leishimaniasis in 2014 in Jiashi County of Xinjiang","volume":"33","author":"Osman","year":"2015","journal-title":"Chin J Parasitol Parasit Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e6559","DOI":"10.1371\/journal.pntd.0006559","article-title":"The burden of Neglected Tropical Diseases in Brazil, 1990-2016: A subnational analysis from the Global Burden of Disease Study 2016","volume":"12","author":"Martins-Melo","year":"2018","journal-title":"PLoS Neg Trop Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/qjmed\/hct116","article-title":"Leishmaniasis: clinical syndromes and treatment","volume":"107","author":"McGwire","year":"2013","journal-title":"QJM."},{"key":"B12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S003118201600216X","article-title":"Leishmaniasis and various immunotherapeutic approaches","volume":"145","author":"Taslimi","year":"2018","journal-title":"Parasitology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3969\/j.issn.1000-3606.2017.04.017","article-title":"Liposomal amphotericin B successfully in treatment of Kala-Azar with antimonial resistance in a child: a case report and literature review","volume":"35","author":"Yuan","year":"2017","journal-title":"J Clin Pediatr Vol."},{"key":"B15","first-page":"1","year":"2010","journal-title":"World Health Organ Tech Rep Ser"},{"key":"B16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4269\/ajtmh.15-0408","article-title":"Social and economic burden of human leishmaniasis","volume":"94","author":"Okwor","year":"2016","journal-title":"Am J Trop Med Hyg."},{"key":"B17","first-page":"355","article-title":"Advances in the Development of Leishmaniasis Vaccine","volume":"37","author":"Malalie","year":"2020","journal-title":"Dermatology Bulletin."},{"key":"B18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S1473-3099(10)70320-0","article-title":"Visceral leishmaniasis: elimination with existing interventions","volume":"11","author":"Matlashewski","year":"2011","journal-title":"Lancet Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.13748\/j.cnki.issn1007-7693.2019.11.025","article-title":"Systematic classification of antifungal drugs, resistance mechanisms and development of new drugs","volume":"36","author":"Xiaoyan","year":"2019","journal-title":"Chin J Mod Appl Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat Chem Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: Current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac J Trop Med."},{"key":"B22","first-page":"156","article-title":"Treatment of antimony-resistant visceral leishmaniasis with domestic amphotericin B: a case report","volume":"25","author":"Chen","year":"2007","journal-title":"Chinese Journal of Parasitology and Parasitic Diseases."},{"key":"B23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/0974-777X.62886","article-title":"Treatment of 2 cases of antimony-resistant visceral leishmaniasis with domestic amphotericin B: case report","volume":"28","author":"Yuan","year":"2010","journal-title":"Chinese Journal of Parasitology and Parasitic Diseases."},{"key":"B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.19538\/j.nk2017040123","article-title":"Successful treatment for a patient with visceral leishmaniasis by amphotericin B","volume":"37","author":"Huo","year":"2017","journal-title":"Chinese Journal of Practical Internal Medicine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11908-999-0052-0","article-title":"Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development","volume":"1","author":"Pearson","year":"1999","journal-title":"Curr Infect Dis Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/1120009X.2017.1306183","article-title":"Liposomal amphotericin B (AmBisome(R)) at beginning of its third decade of clinical use","volume":"29","author":"Aversa","year":"2017","journal-title":"J Chemother."},{"key":"B27","first-page":"210","article-title":"Analysis of the administration regimen of amphotericin B liposome in the treatment of pulmonary fungal infection","volume":"2","author":"Lang","year":"2018","journal-title":"Journal Of Imaging Research And Medical Applications."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.766400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T07:01:02Z","timestamp":1637132462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.766400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":27,"alternative-id":["10.3389\/fmed.2021.766400"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.766400","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"article-number":"766400"}}